Connect with us

Hi, what are you looking for?

Health

Allegro Appoints Stephan Crokaert as COO to Propel Osteoarthritis Treatment

Allegro NV has appointed Stephan Crokaert as its new Chief Operating Officer, effective September 1, 2025. This strategic move aims to bolster the management team as the company prepares to advance its lead product, hydrocelin, into clinical trials by 2026. Based in Liege, Belgium, Allegro is focused on developing innovative nanotechnology-based treatments for degenerative joint diseases.

The announcement highlights Allegro’s commitment to enhancing its clinical and commercial capabilities in the face of a significant unmet need for effective osteoarthritis treatments. Lucas Decuypere, CEO of Allegro, expressed enthusiasm about Crokaert’s extensive background in the life sciences sector, stating, “We are pleased to welcome such an experienced life science professional as Stephan Crokaert to the management team. His appointment comes at a crucial moment for Allegro, as we prepare our potential first-in-class treatment for osteoarthritis for clinical trials.”

Crokaert brings over 35 years of strategic and commercial experience to the role, having previously held notable positions at NeoMedLight, Abbott, Adagio, and Boston Scientific. His recent role as Global Sales and Market Director at NeoMedLight involved establishing a global commercial network, underscoring his capability to drive growth in the medical device industry.

“I am delighted to join the driven and successful team at Allegro. I look forward to leveraging my experience to advance the company’s promising technology and bring an innovative first-in-class treatment for osteoarthritis to market,” Crokaert said.

Allegro recently secured €2 million in funding, demonstrating strong support from key investors. This capital will be utilized to prepare hydrocelin for a feasibility study in patients with osteoarthritis in 2026, followed by a global registrational trial. The company has also completed the installation of a scalable manufacturing device in a cleanroom environment, capable of producing up to 15,000 prefilled syringes per batch.

Hydrocelin is designed to contain cross-linked microparticles that act as miniature shock absorbers in the synovial fluid of joints affected by osteoarthritis. The innovative treatment aims to restore the shock-absorbing capacity of synovial fluid, providing pain relief and protecting cartilage. It is intended to be administered by injection once a year.

In April, Allegro showcased promising preclinical data at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases held in Rome. The data indicated a satisfactory safety profile for hydrocelin, including findings from studies on irritation, delayed sensitization, and systemic toxicity.

Allegro NV is a private biomedical company committed to developing transformative treatments for degenerative joint diseases through its proprietary nanotechnology platform known as INTRICATE. With clinical studies anticipated later this year, the company is on track for a commercial launch in 2027.

The information included in this announcement contains forward-looking statements regarding future performance. These statements involve risks and uncertainties, and actual results may differ materially from those predicted. The company does not undertake any obligation to publicly update or revise these statements unless required by law. For more details, visit www.allegro.bio.

You May Also Like

Technology

Tesla (TSLA) recently reported a year-over-year drop in second-quarter deliveries, yet the market responded with optimism, pushing the stock up by 5%. This unexpected...

Health

The All England Lawn Tennis Club in London experienced its hottest-ever opening day on Monday, as the prestigious Wimbledon tournament kicked off under unprecedented...

Science

Look out, daters: a new toxic relationship trend is sweeping through the romantic world, leaving many baffled and heartbroken. Known as “Banksying,” this phenomenon...

Technology

In a bold reimagining of the DC Universe, director James Gunn has introduced a significant narrative element in his latest film, which reveals that...

Entertainment

Netflix’s eagerly anticipated talent competition Building the Band is set to premiere on July 9, promising an emotional journey for viewers. This series, centered...

Technology

Former Speaker of the House Nancy Pelosi has recently made headlines with her latest investment in the tech sector. According to official filings, she...

Entertainment

A new documentary series titled “Animals on Drugs” is set to premiere on the Discovery Channel on July 28, 2023. The three-part series follows...

Technology

The answer to today’s NYT Wordle, dated August 8, 2025, is the verb IMBUE. This word, which means “to fill or saturate,” features three...

World

The first dose of the hepatitis B vaccine is recommended at birth, a practice that has come under scrutiny following recent comments by Health...

Technology

The Evo 2025 tournament is set to take place from August 1 to August 3, 2025, showcasing some of the most popular fighting games...

Sports

ZAGREB, Croatia — A concert by Marko Perkovic, a right-wing Croatian singer known for his controversial views, attracted tens of thousands of fans to...

Business

Erin Dana Lichy, a prominent cast member of “Real Housewives of New York,” has officially settled into her dream home, a grand townhouse located...

Politics

Billionaire hedge fund manager Bill Ackman faced significant backlash following his professional tennis debut at the Hall of Fame Open in Newport, Rhode Island,...

Lifestyle

The upcoming TRNSMT 2025 festival is set to take place from July 7 to July 9, 2025, at Glasgow Green, and organizers have released...

Sports

As the summer of 2025 unfolds, the video game industry is set to deliver a diverse array of new releases that promise to captivate...

Entertainment

While the echoes of Summer Game Fest 2025 and the Xbox Games Showcase still resonate, Xbox has already set its sights on the next...

Copyright © All rights reserved. This website provides general news and educational content for informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the information presented. The content should not be considered professional advice of any kind. Readers are encouraged to verify facts and consult appropriate experts when needed. We are not responsible for any loss or inconvenience resulting from the use of information on this site.